FOXO4-DRI: research profile
Last updated Oct 8, 2026 · research counts checked Oct 7, 2026
Identity
- Name
- FOXO4-DRI
- Also called
- FOXO4 D-retro-inverso peptide
- Molecular formula
- C228H388N86O64
- Molecular weight
- 5358 g/mol
- CAS number
- 2460055-10-9
- Source
- PubChem CID 167312269 ↗
A peptide made of D-amino acids in reversed order (a D-retro-inverso design) derived from part of the FOXO4 protein.
Sequences are shown only where the formula calculated from the sequence matches PubChem's formula exactly; CAS numbers only where the PubChem record lists a single valid one.
Published research record
Counts of database records matching the compound's names, as of Oct 7, 2026. They describe how much has been published and in what kind of study, not what any study found.
| Record type | Count | Source |
|---|---|---|
| PubMed records (any study type) | 19 | PubMed search ↗ |
| …indexed as animal studies, with no human tag | 5 | PubMed search ↗ |
| …indexed as clinical trials (in people) | 0 | PubMed search ↗ |
| …indexed as reviews | 5 | PubMed search ↗ |
| ClinicalTrials.gov registered studies | 0 | ClinicalTrials.gov search ↗ |
PubMed query: "FOXO4-DRI"[tiab] OR "FOXO4 D-retro-inverso"[tiab]. ClinicalTrials.gov query: "FOXO4-DRI". PubMed's study-type tags are added by indexers and lag new records, and keyword matches can include records that only mention the compound, so read these as rough counts.
Regulatory status
- FDA (compounding): Not named on FDA's Category 2 bulk-drug-substances page (checked Oct 7, 2026). FDA source ↗
- Research peptides from both vendors are sold for laboratory research use only, not for human or veterinary consumption. This summary isn't legal or regulatory advice.
Lab-tested FOXO4-DRI lots (3)
| Lot | Vendor · product | Report date | Lab | HPLC purity | Identity |
|---|---|---|---|---|---|
| FOX15N030826 | Paramount Peptides · FOXO4-DRI (15mg) | Apr 17, 2026 | Janoshik | 99.80% | Not reported |
| FOX15N021426 | Paramount Peptides · FOXO4-DRI (15mg) | Feb 27, 2026 | Janoshik | 99.73% | Not reported |
| FOX10-001 | Peptira · FOX04-DRI Vial 10 mg | Nov 9, 2025 | Freedom Diagnostics | 99.83% | Mass identified as FOX04-DRI (LC-MS) |
Doses reported in published studies: FOXO4-DRI: doses reported in published research (literature summary, not advice).
Organ systems in published research: Heart & blood vessels, Kidney & urinary tract, Skin, Bone & cartilage, Lungs & airways, Reproductive organs & breast.